Seelos Therapeutics (SEELQ) 10-K 4 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 04, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-22245
Entity Registrant Name	SEELOS THERAPEUTICS, INC.
Entity Central Index Key	0001017491
Entity Tax Identification Number	87-0449967
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	300 Park Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	646
Local Phone Number	293-2100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SEEL
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 261.5
Entity Common Stock, Shares Outstanding		105,506,695
Documents Incorporated by Reference [Text Block]	Certain information required to be disclosed in Part III of this report is incorporated by reference from the information contained in the registrant's Definitive Proxy Statement for the 2022 Annual Meeting of Stockholders, which Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021.
ICFR Auditor Attestation Flag	false
Entity Listing, Par Value Per Share	$ 0.001
Auditor Name	KPMG LLP
Auditor Location	Short Hills, NJ
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 78,734,000	$ 15,662,000
Prepaid expenses and other current assets	4,727,000	1,832,000
Total current assets	83,461,000	17,494,000
Operating lease right-of-use asset	39,000
Total assets	83,500,000	17,494,000
Current liabilities
Accounts payable	1,693,000	1,887,000
Accrued expenses	3,728,000	1,924,000
Licenses payable	200,000	125,000
Convertible debt		2,431,000
Short-term portion of convertible notes payable, at fair value	1,030,000
Derivative liability	1,174,000
Warrant liabilities, at fair value	424,000	1,062,000
Operating lease liability	38,000
Total current liabilities	8,287,000	7,429,000
Licenses payable, long-term		200,000
Note payable		147,000
Convertible notes payable, at fair value	17,890,000
Convertible debt, long-term		7,146,000
Total liabilities	26,177,000	14,922,000
Commitments and contingencies (note 13)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares          issued or outstanding as of December 31, 2021 and December 31, 2020
Common stock, $0.001 par value, 240,000,000 and 120,000,000 shares authorized,          105,500,445 and 54,535,891 issued and outstanding as of          December 31, 2021 and December 31, 2020, respectively	105,000	54,000
Additional paid-in-capital	198,428,000	77,680,000
Accumulated deficit	(141,210,000)	(75,162,000)
Total stockholders’ equity	57,323,000	2,572,000
Total liabilities and stockholders’ equity	$ 83,500,000	$ 17,494,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, per value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	240,000,000	120,000,000
Common stock, issued (in shares)	105,500,445	54,535,891
Common stock, outstanding (in shares)	105,500,445	54,535,891

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expense
Research and development	$ 46,649	$ 10,984
General and administrative	15,020	7,775
Total operating expense	61,669	18,759
Loss from operations	(61,669)	(18,759)
Other income (expense)
Interest income	113	45
Interest expense	(1,598)	(164)
Change in fair value of derivative liability	(369)
Change in fair value of convertible notes	230
Net loss on extinguishment of debt	(2,387)
Gain on forgiveness of debt	149
Change in fair value of warrant liabilities	(517)	(223)
Total other income (expense)	(4,379)	(342)
Net loss and comprehensive loss	$ (66,048)	$ (19,101)
Net loss per share basic and diluted	$ (0.73)	$ (0.43)
Weighted-average common shares outstanding basic and diluted	90,890,061	44,766,640

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 27	$ 56,027	$ (56,061)	$ (7)
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2019	27,028,533
Stock-based compensation expense		2,044		2,044
Issuance of common stock for prepaid services		330		330
[custom:IssuanceOfCommonStockForPrepaidServicesShares]	400,000
Issuance of common stock for license acquired	$ 2	2,441		2,443
Issuance of common stock, net of issuance costs	$ 15	8,835		8,850
Issuance of common stock for license acquired, shares	1,809,845
Issuance of common stock, net of issuance costs, shares	15,166,666
Net Income (Loss) Attributable to Parent			(19,101)	(19,101)
Warrants exercised for cash		169		$ 169
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2020	54,535,891			54,535,891
Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs	8,865,000
Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs, shares	1,112,219
Warrants exercised for cash, shares	153,628
Issuance of common stock and warrants, pursuant to     Securities Purchase Agreement, net of issuance costs	$ 1	1,378		$ 1,379
Issuance of common stock and warrants, pursuant to     September 2020 Securities Purchase Agreement,     net of issuance costs	9	6,356		6,365
Net loss			(19,101)	(19,101)
Ending balance, value at Dec. 31, 2020	54	77,680	(75,162)	2,572
Stock-based compensation expense		8,347		8,347
Issuance of common stock, options exercised		102		102
Issuance of common stock, options exercised, shares	79,138
Issuance of common stock for license acquired	$ 3	4,830		4,832
Issuance of common stock for settlement of debt		1,377		1,377
Issuance of common stock, net of issuance costs	$ 40	97,917		97,957
Issuance of common stock for license acquired, shares	2,570,266
Issuance of common stock, net of issuance costs, shares	39,788,554
Net Income (Loss) Attributable to Parent			(66,048)	(66,048)
Warrants exercised for cash	$ 7	8,401		$ 8,408
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021	105,500,445			105,500,445
custom:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement	540,147
[custom:IssuanceOfCommonStockForConversionOfDebtShares]	69,065
[custom:IssuanceOfCommonStockForExtinguishmentOfDebtShares]	406,250
Warrants exercised for cash, shares	7,431,125
Net loss			(66,048)	$ (66,048)
Extinguishment of beneficial conversion feature		(1,519)		(1,519)
Issuance of common stock for conversion of debt		138		138
Issuance of common stock, ESPP		104		104
Issuance of common stock, ESPP, shares	80,009
Issuance of common stock, pursuant to 2021     Securities Purchase Agreements	$ 1	1,051		1,052
Ending balance, value at Dec. 31, 2021	$ 105	$ 198,428	$ (141,210)	$ 57,323

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (66,048)	$ (19,101)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	8,347	2,044
Shares issued for services		124
Research and development expenses - license acquired	5,637	192
Change in fair value of warrant liability	517	223
Change in fair value of convertible notes payable	(230)
Change in fair value of derivative liability	369
Gain on forgiveness of note payable	(149)
Net loss on extinguishment of convertible debt	2,387
Amortization of debt discount	1,582	150
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(2,894)	(791)
Accounts payable	(194)	1,091
Accrued expenses	1,806	5
Licenses payable	(125)	(4,850)
Net cash used in operating activities	(48,995)	(20,913)
Cash flows provided by financing activities
Payment of convertible note	(13,551)
Proceeds from issuance of common stock, net of issuance costs	97,957	8,850
Proceeds from issuance of common stock and convertible notes payable	20,203	10,907
Proceeds from issuance of common stock and warrants, pursuant to          Securities Purchase Agreement, net of issuance costs		6,365
Proceeds from exercise of warrants	7,252	45
Proceeds from exercise of options	102
Proceeds from sales of common stock under ESPP	104
Proceeds from note payable		147
Net cash provided by financing activities	112,067	26,314
Net increase in cash	63,072	5,401
Cash, beginning of period	15,662	10,261
Cash, end of period	78,734	15,662
Supplemental disclosure of cash flow information:
Cash paid for interest	10	11
Cash paid for income taxes
Non-cash investing and financing activities:
Reclass of warrant liabilities related to Series A warrants exercised for cash	1,155	124
Right-of-use assets obtained in exchange for operating lease liabilities	75
Issuance of common stock for convertible notes	69
Issuance of common stock for settlement of debt	1,377
Extinguishment of beneficial conversion feature	1,519
Issuance of common stock for iX Biopharma license	4,832
Issuance of common stock for license payable		$ 2,443

1. Organization and Summary of

1. Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization Seelos Therapeutics, Inc. and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Fair Value of Financial Instruments The carrying amounts of financial instruments such as accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments. Leases The Company determines if an arrangement is a lease at inception. Fair Value Option As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred. Fair Value Measurements The Company follows the accounting guidance in the FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Research and Development Research and development costs are expensed as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements in place. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. Income (Loss) Per Common Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding for the year ended December 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended December 31, 2021 2020 Outstanding stock options 7,306 5,120 Restricted stock units 2,400 - Outstanding warrants 2,635 10,066 Convertible debt 3,704 8,556 16,045 23,742 Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company. Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed. Segment Information The Company operates under one segment which develops pharmaceutical products. Recent Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of ASU 2019-12 did not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures.

2. Liquidity and Going Concern

2. Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2. Liquidity and Going Concern	2. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company has limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2021, the Company had $ 78.7 141.2 The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the release date of this Annual Report on Form 10-K. Based on such evaluation and the Company's current plans (including the ongoing clinical programs for SLS-002, SLS-005; and other product candidates), which are subject to change, management believes that the Company’s existing cash and cash equivalents as of December 31, 2021 are not sufficient to satisfy its operating cash needs for at least one year. The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.

3. Business Combination

3. Business Combination	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
3. Business Combination	3. Business Combination On January 24, 2019, the Company (which was formerly known as “Apricus Biosciences, Inc.”) (“Apricus”) completed the business combination with Seelos Therapeutics, Inc., a Delaware corporation (“STI”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization entered into on July 30, 2018 (the “Merger Agreement”). Pursuant to the Merger Agreement, (i) a former subsidiary of the Company merged with and into STI, with STI (renamed “Seelos Corporation”) continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger and (ii) the Company was renamed “Seelos Therapeutics, Inc.” (the “Merger”). The Merger was accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Apricus were nominal at the close of the Merger. STI was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons holding securities convertible, exercisable or exchangeable directly or indirectly for STI common stock owned the majority of the Company immediately following the effective time of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company, and (iii) STI’s management holds all key positions in the management of the combined company. STI acquired no tangible assets and assumed no employees or operation from Apricus. Additionally, Apricus’ intellectual property was considered to have no value. The remaining Apricus liabilities had a fair value of approximately $300 thousand. In connection with the Merger, the Company and STI entered into a Contingent Value Rights Agreement (the “CVR Agreement”). Pursuant to the CVR Agreement, Apricus stockholders received one contingent value right (“CVR”) for each share of Apricus common stock held of record immediately prior to the closing of the Merger. Each CVR represents the right to receive payments based on Apricus’ U.S. assets related to products in development, intended for the topical treatment of erectile dysfunction, which are known as Vitaros in certain countries outside of the United States (the “CVR Product Candidate”). In particular, CVR holders will be entitled to receive 90% of any cash payments (or the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the Merger, based on the sale or out-licensing of Apricus’ CVR Product Candidate intangible asset, including any milestone payments (the “Contingent Payments”), less reasonable transaction expenses. The Company is entitled to retain the first $500,000 and 10% of any Contingent Payments. The Company has agreed to pay up to $500,000 of such Contingent Payments that it receives to a third party pursuant to a settlement agreement between the Company and the third party. The Company assigned no value to the CVR Product Candidate intangible asset as of December 31, 2021 or the CVR in the acquisition accounting.

4. Fair Value Measurement

4. Fair Value Measurement	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
4. Fair Value Measurement	4. Fair Value Measurement The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. At time of issuance, the derivative liability at fair value was recognized using Level 3 inputs as no observable inputs were available at the time in the market. At December 31, 2021, the derivative liability has been reclassed as a Level 1 input as the significant inputs were known and observable. There were no Schedule of Fair Value Hierarchy Assets and Liabilities Fair Value Measurements as of December 31, 2021 (Level 1) (Level 2) (Level 3) Total Assets Cash $ 78,734 $ - $ - $ 78,734 Liabilities Convertible notes payable, at fair value $ - $ - $ 18,920 $ 18,920 Derivative liability, at fair value 1,174 - - 1,174 Warrant liabilities, at fair value - - 424 424 $ 1,174 $ - $ 19,344 $ 20,518 Fair Value Measurements as of December 31, 2020 (Level 1) (Level 2) (Level 3) Total Assets Cash $ 15,662 $ - $ - $ 15,662 Liabilities Warrant liabilities, at fair value $ - $ - $ 1,062 $ 1,062 The fair value of the Company’s money market funds is based on quoted active market prices for the funds and is determined using the market approach. The Company measures the 2021 Convertible Notes, derivative liability and warrant liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. The fair value of the convertible notes payable, derivative liability and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. Derivative Liability The derivative liability represents the fair value of the “Shortfall Amount” provision provided for in the license agreement with iX Biopharma Europe Limited. See Note 7. At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. Summary of Fair Value Measurements Derivative Valuation Assumptions Year Ended December 31, 2021 Risk-free interest rate 0.13% Volatility 110% Dividend yield - Expected term (years) 0.11 Stock price $ 1.88 2021 Convertible Notes The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes as of December 31, 2021: Summary of Fair Value Measurements Convertible Notes Valuation Assumptions Year Ended December 31, 2021 Risk-free interest rate 0.90 0.95 Volatility 113 114 Dividend yield - Contractual term (years) 3 Stock price $ 1.74 1.95 Warrant Liabilities The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2021 and 2020: Summary of Fair Value Measurements Warrant Valuation Assumptions Year Ended December 31, 2021 2020 Risk-free interest rate 0.75% 0.18% Volatility 110.55% 116.77% Dividend yield - - Expected term (years) 2.07 3.07 Weighted-average fair value $ 1.40 $ 1.40 The following table is a reconciliation for the common stock warrant liabilities, derivative liability, and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): Schedule of Fair Value Level 3 Reconciliation Warrant Derivative Convertible notes, liabilities liability at fair value Balance as of December 31, 2019 $ 963 $ - $ - Warrant liability reclassified to stockholders' equity (124) - - Change in fair value measurement of warrant liability 223 - - Balance as of December 31, 2020 $ 1,062 $ - $ - Warrant liability reclassified to stockholders' equity (1,155) - - Issuance of convertible notes, at fair value - - 19,150 Issuance of derivative liability - 805 - Change in fair value measurement of derivative liability - 369 - Change in fair value measurement of convertible notes - - (230) Change in fair value measurement of warrant liability 517 - - Balance as of December 31, 2021 $ 424 $ 1,174 $ 18,920 For the years ended December 31, 2021 and 2020, the changes in fair value of the convertible notes, derivative liability and warrant liability primarily resulted from the volatility of the Company’s common stock.

5. Prepaid Expenses and Other C

5. Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
5. Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following (in thousands): Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 2020 Prepaid insurance $ 59 $ 50 Prepaid clinical costs 4,481 1,743 Other 187 39 Prepaid expenses and other current assets $ 4,727 $ 1,832

6. Common Stock Offerings

6. Common Stock Offerings	12 Months Ended
	Dec. 31, 2021
Common Stock Offerings
6. Common Stock Offerings	6. Common Stock Offerings Securities Purchase Agreements November 2021 and December 2021 Convertible Notes and Private Placement Between November 2021 and December 2021, the Company issued an aggregate of 540,147 20.2 December 2020 Convertible Note and Private Placement In December 2020, the Company sold 1,112,219 10.9 2020 Registered Direct Offering and Concurrent Private Placement On September 4, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors (the “2020 Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of 8,865,000 6.4 The Company also issued to the investors warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the "September 2020 Warrants"). The September 2020 Warrants have an exercise price of $0.84 per share of common stock, became exercisable beginning on March 9, 2021 and will expire on March 9, 2026. The combined purchase price for one share and one warrant to purchase 0.75 of a share of common stock in the offerings was $ 0.79 2019 Registered Direct Offering and Concurrent Private Placement On August 23, 2019, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate of 4,475,000 6.7 The Company issued to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC (“Roth”) served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company in the offerings. Public Offerings On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 3.10 64.5 7.3 On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 2.05 33.5 3.8 On March 16, 2020, the Company completed an underwritten public offering pursuant to which it sold 7,500,000 0.60 4.0 On February 13, 2020, the Company completed an underwritten public offering, pursuant to which it sold 6,666,667 0.75 999,999 0.75 4.8 Stock Purchase Agreement with iX Biopharma Europe Limited On November 24, 2021, the Company entered in an exclusive license agreement and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”). As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $ 9.0 3.5 2,570,266 2,570,266 5.5 0.8 1.2 Stock Purchase Agreement with Vyera On January 2, 2020, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Vyera, pursuant to which the Company issued to Vyera 1,809,845 Consulting Agreement On May 11, 2020, the Company entered into a consulting agreement (the “Consulting Agreement”) with an advisory firm, pursuant to which the advisory firm agreed to provide the Company with certain management consulting, business and advisory services. The Company agreed to issue the advisory firm 300,000 During the year ended December 31, 2020, the Company recognized approximately $ 431,000 Pre-Merger Financing On January 24, 2019, STI and Apricus closed a private placement transaction with certain accredited investors (the “Investors”), whereby, among other things, STI issued to investors shares of STI’s common stock immediately prior to the Merger in a private placement transaction (the “Financing”), pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors, as amended (the “Purchase Agreement”). Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STI’s common stock which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company’s common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein (the “Series A Warrants”), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein (the “Series B Warrants” together with the Series A Warrants, the “Investor Warrants”), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 10). The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given that the liability exceeded the proceeds received, a loss of $5.0 million was recognized. On March 7, 2019, the Company entered into Amendment Agreements (collectively, the “Amendment Agreements”) with each Investor amending: (i) the Purchase Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements. At December 31, 2021, 0.3

7. License Agreements

7. License Agreements	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
7. License Agreements	7. License Agreements Acquisition of License from Ligand Pharmaceuticals Incorporated On September 21, 2016, the Company entered into a License Agreement (the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products. In connection with the closing of the Merger, the Company issued 801,253 2.2 The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $ 750,000 3.0 1.125 1.125 The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $ 100,000 350,000 125,000 125,000 The Company agreed to pay to Ligand certain one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $ 10.0 10.0 10.0 10.0 20.0 20.0 20.0 20.0 The Company will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD n or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent. The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (“Vyera”) On March 6, 2018, the Company entered into the Vyera Agreement with Vyera, pursuant to which the Company acquired the assets (the “Vyera Assets”) and liabilities (the “Vyera Assumed Liabilities”), of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002 As consideration for the Vyera Assets, the Company paid to Vyera a non-refundable cash payment of $ 150,000 150,000 191,529 1,000,000 Pursuant to the amendment to the Asset Purchase Agreement entered into by the Company and Vyera on October 15, 2019, the Company issued Vyera 1,809,845 750,000 750,000 1.0 1.0 Pursuant to the amendment to the asset purchase agreement entered into with Vyera on February 15, 2021, the Company made cash payments to Vyera in the amount of $ 3.0 In the event that the Company sells, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale. The Company agreed to pay to Vyera certain one-time, non-refundable milestone payments consisting of (i) $ 10.0 5.0 2.5 5.0 10.0 15.0 20.0 25.0 The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of License from Stuart Weg, MD On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $ 0.2 0.1 0.125 0.1 0.15 0.5 3.0 2.0 1.5 6.6 2.25% The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of Assets from Bioblast Pharma Ltd. (“Bioblast”) On February 15, 2019, the Company entered into an Asset Purchase Agreement (the “Bioblast Asset Purchase Agreement”) with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the “Bioblast Asset Purchase”). The Company paid to Bioblast $ 1.5 2.0 3.5 8.5 8.5 1% 1.5 The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of License from The Regents of the University of California On March 7, 2019, the Company entered into an exclusive license agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $ 0.1 0.1 50,000 0.1 0.3 1.0 1.0 2.5 The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of License from Duke University On June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the synuclein alpha (“SNCA”) gene, which encodes alpha-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $ 0.1 0.1 0.1 0.2 0.5 1.0 2.0 The potential regulatory and commercial milestones are not yet considered probable, and no Acquisition of License from iX Biopharma Europe Limited On November 24, 2021, the Company entered into an exclusive license agreement (the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of Wafermine ™ As consideration for the license under the iX License Agreement, the Company agreed to (i) pay iXBEL an upfront fee of $ 9.0 3.5 2,570,266 Pursuant to the iXBEL Stock Purchase Agreement, the Company also agreed to reimburse iXBEL for the Shortfall Amount in the event the aggregate value of the 2,570,266 5.5 1.2 1.2

8. Accrued Expenses

8. Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
8. Accrued Expenses	8. Accrued Expenses Accrued expenses are comprised of the following (in thousands): Schedule of Accrued Liabilities December 31, 2021 2020 Professional fees $ 181 $ 292 Personnel related 1,303 756 Outside research and development services 2,219 764 Other 25 112 Accrued expenses, net $ 3,728 $ 1,924

9. Debt

9. Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
9. Debt	9. Debt Convertible Notes November 2021 and December 2021 Convertible Notes and Private Placement On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock. At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note. At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August 23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2021 Notes, unless waived by Lind V in advance. Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties. On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note. The Company received aggregate gross proceeds of $ 20.2 19.2 0.2 18.9 As of December 31, 2021, the principal contractual balance of the notes totaled $22.2 million. Scheduled maturities with respect to the 2021 Convertible Notes are as follows (in thousands): Maturities of Long-term Debt Year Ending December 31: 2022 $ 917 2023 $ 11,111 2024 $ 10,194 2025 $ - 2026 $ - Total $ 22,222 December 2020 Convertible Note and Private Placement On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of our remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021. On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of our remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021. The Company received aggregate net proceeds of $10.9 million from the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million as of December 31, 2021. During the year ended December 31, 2021, the Company paid approximately $13.6 million in principal payments on the outstanding convertible notes and issued an aggregate of 475,315 shares of its common stock upon conversion of the convertible notes, and none of the 2020 convertible notes remain outstanding as of December 31, 2021. PPP Loan On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the “PPP Lender”), for an aggregate principal amount of approximately $ 147,000 1.0

10. Stockholders' Equity

10. Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
10. Stockholders' Equity	10. Stockholders' Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 No Common Stock The Company has authorized 240,000,000 120,000,000 Each share of common stock is entitled to one voting right Warrants September 2020 Warrants The September 2020 Warrants are exercisable for 6,648,750 0.84 March 9, 2021 During the year ended December 31, 2021, September 2020 Warrants were exercised for 5.6 4.7 1.0 million 0.84 August 2019 Warrants On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 February 27, 2020 During the year ended December 31, 2021, August 2019 Warrants for 1.3 2.4 900,000 1.78 Series A Warrants The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024. During the year ended December 31, 2021 and 2020, Series A Warrants for 0.5 million and 0.2 million shares of common stock, respectively, were exercised for approximately $ 0.1 million and $ 45,000 , respectively. As of December 31, 2021, Series A Warrants exercisable for 0.3 million shares of common stock remain outstanding at an exercise price of $ 0.2957 per share A summary of warrant activity during the year ended December 31, 2021 is as follows (in thousands): Summary of Warrant Activity Weighted- Weighted- Average Average Remaining Exercise Contractual Life Warrants Price (in years) Outstanding as of December 31, 2019 3,584 $ 3.86 Issued 6,648 $ 0.84 Exercised (154) $ 0.30 Cancelled (12) $ 18.00 Outstanding as of December 31, 2020 10,066 $ 1.84 4.4 Issued - $ - Exercised (7,431) $ 0.98 Cancelled - $ - Outstanding as of December 31, 2021 2,635 $ 4.29 2.4 Exercisable as of December 31, 2021 2,635 $ 4.29 2.4 The Series A Warrants were recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.

11. Stock-Based Compensation

11. Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
11. Stock-Based Compensation	11. Stock-Based Compensation The Company has the Amended and Restated Apricus 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. As of December 31, 2021, an aggregate of 11,110,431 1.4 On May 15, 2020, the Company’s stockholders approved the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”), whereby qualified employees are allowed to purchase limited amounts of the Company’s common stock at the lesser of 85 1.0 On January 1, 2021, the Company added 545,358 shares for purchase by employees under the ESPP. 80,009 72,000 On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan is substantially similar to the 2016 Plan. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 Stock options During the year ended December 31, 2021, the Company granted 2,210,000 4.04 During the year ended December 31, 2021, the Company also granted 106,000 1.67 The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following assumptions were used in determining the fair value of the stock options granted during the years ended December 31, 2021 and 2020: Schedule of Valuation Assumptions for Stock Options Year Ended December 31, 2021 2020 Risk-free interest rate 0.5 1.2 0.3 1.7 Volatility 118 125 109 119 Dividend yield - - Expected term (years) 5 6 5 7 Weighted-average fair value $ 3.46 $ 0.97 A summary of stock option activity during the year ended December 31, 2021 is as follows (in thousands, except exercise prices and years): Schedule of Valuation Assumptions for Stock Options Weighted Weighted Total Average Average Remaining Aggregate Stock Exercise Contractual Intrinsic Options Price Life (in years) Value Outstanding as of December 31, 2020 5,120 $ 1.97 Granted 2,316 3.94 Exercised (81) 1.40 Cancelled (49) 2.06 Outstanding as of December 31, 2021 7,306 $ 2.60 8.5 $ 2,180 Vested and expected to vest as of December 31, 2021 7,306 $ 2.60 8.5 $ 2,180 Exercisable as of December 31, 2021 2,245 $ 2.99 8.1 $ 856 The intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $ 0.3 0 7.4 2.1 Performance Stock Award During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 4.31 4.9 1.3 0.2 4.1 The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands): Schedule of Stock-Based Compensation Expense Year Ended December 31, 2021 2020 Research and development $ 717 $ 394 General and administrative 7,630 1,650 $ 8,347 $ 2,044

12. Income Taxes

12. Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
12. Income Taxes	12. Income Taxes The Company has incurred net operating losses since inception. At December 31, 2021, the Company has available net operating loss carryforwards of approximately $ 89.4 175.5 0.4 2036 89.0 175.5 2036 Deferred tax assets consist of the following (in thousands): Schedule of Deferred Tax Assets December 31, 2021 2020 Net operating tax loss carryforwards $ 30,751 $ 15,223 Accrued expenses - 66 Contingent payment obligations 407 - Stock-based compensation 3,208 521 Intangible assets 16,970 12,320 Total deferred tax asset 51,336 28,130 Less valuation allowance (51,336) (28,130) Net deferred tax asset $ - $ - The federal and state net operating loss carryforwards, not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of December 31, 2021 and 2020 of approximately $ 30.8 15.2 The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's federal income tax returns for 2018 no The Company did not have any unrecognized tax benefits for the years ended December 31, 2021 and 2020. The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2021 and 2020, are as follows: Schedule of Effective Income Tax Rate Reconciliation Year Ended December 31, 2021 2020 Federal statutory tax rate 21.0 % 21.0 % State and local taxes, net of federal benefit 12.9 % 11.2 % Permanent items (1.1) % (1.0) % Deferred rate changes 2.3 % 0.1 % Other 0.0 % 59.3 % Change in valuation allowance (35.1) % (90.6) % Income tax provision (benefit) - % - %

13. Commitments and Contingenci

13. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
13. Commitments and Contingencies	13. Commitments and Contingencies Leases In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019 the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder. In March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement includes one or more renewal options. 39,000 38,000 Upon the commencement of the 300 Park Avenue, New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $ 74,000 0.8 8.0 As of December 31, 2021, future minimum lease payments for the Company’s operating leases with a non-cancelable term of more than one year is as follows (in thousands): Schedule of future minimum operating lease payments Operating Leases Remaining Period Ended December 31, 2021 $ - Year Ended December 31, 2022 40 Total 40 Less present value discount (2) Operating lease liabilities $ 38 For the years ended December 31, 2021 and 2020, rent expense totaled $ 0.1 Contractual Commitments The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash. Litigation As of December 31, 2021, there was no material litigation against the Company.

14. Subsequent Events

14. Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
14. Subsequent Events	14. Subsequent Events In January 2022, the Company paid to iXBEL the Shortfall Amount (as described in Note 4) of $ 1.2

1. Organization and Summary o_2

1. Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Seelos Therapeutics, Inc. and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of financial instruments such as accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments.
Leases	Leases The Company determines if an arrangement is a lease at inception.
Fair Value Option	Fair Value Option As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.
Fair Value Measurements	Fair Value Measurements The Company follows the accounting guidance in the FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Research and Development	Research and Development Research and development costs are expensed as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements in place.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
Income (Loss) Per Common Share	Income (Loss) Per Common Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding for the year ended December 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended December 31, 2021 2020 Outstanding stock options 7,306 5,120 Restricted stock units 2,400 - Outstanding warrants 2,635 10,066 Convertible debt 3,704 8,556 16,045 23,742
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company. Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.
Segment Information	Segment Information The Company operates under one segment which develops pharmaceutical products.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of ASU 2019-12 did not have a material effect on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures.

1. Organization and Summary o_3

1. Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive securities outstanding for the year ended December 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Year Ended December 31, 2021 2020 Outstanding stock options 7,306 5,120 Restricted stock units 2,400 - Outstanding warrants 2,635 10,066 Convertible debt 3,704 8,556 16,045 23,742

4. Fair Value Measurement (Tabl

4. Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Fair Value Hierarchy Assets and Liabilities	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. At time of issuance, the derivative liability at fair value was recognized using Level 3 inputs as no observable inputs were available at the time in the market. At December 31, 2021, the derivative liability has been reclassed as a Level 1 input as the significant inputs were known and observable. There were no Schedule of Fair Value Hierarchy Assets and Liabilities Fair Value Measurements as of December 31, 2021 (Level 1) (Level 2) (Level 3) Total Assets Cash $ 78,734 $ - $ - $ 78,734 Liabilities Convertible notes payable, at fair value $ - $ - $ 18,920 $ 18,920 Derivative liability, at fair value 1,174 - - 1,174 Warrant liabilities, at fair value - - 424 424 $ 1,174 $ - $ 19,344 $ 20,518 Fair Value Measurements as of December 31, 2020 (Level 1) (Level 2) (Level 3) Total Assets Cash $ 15,662 $ - $ - $ 15,662 Liabilities Warrant liabilities, at fair value $ - $ - $ 1,062 $ 1,062
Schedule of Fair Value Level 3 Reconciliation	The following table is a reconciliation for the common stock warrant liabilities, derivative liability, and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): Schedule of Fair Value Level 3 Reconciliation Warrant Derivative Convertible notes, liabilities liability at fair value Balance as of December 31, 2019 $ 963 $ - $ - Warrant liability reclassified to stockholders' equity (124) - - Change in fair value measurement of warrant liability 223 - - Balance as of December 31, 2020 $ 1,062 $ - $ - Warrant liability reclassified to stockholders' equity (1,155) - - Issuance of convertible notes, at fair value - - 19,150 Issuance of derivative liability - 805 - Change in fair value measurement of derivative liability - 369 - Change in fair value measurement of convertible notes - - (230) Change in fair value measurement of warrant liability 517 - - Balance as of December 31, 2021 $ 424 $ 1,174 $ 18,920
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Fair Value Measurements Warrant Valuation Assumptions	At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. Summary of Fair Value Measurements Derivative Valuation Assumptions Year Ended December 31, 2021 Risk-free interest rate 0.13% Volatility 110% Dividend yield - Expected term (years) 0.11 Stock price $ 1.88
Long-term Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Fair Value Measurements Warrant Valuation Assumptions	The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes as of December 31, 2021: Summary of Fair Value Measurements Convertible Notes Valuation Assumptions Year Ended December 31, 2021 Risk-free interest rate 0.90 0.95 Volatility 113 114 Dividend yield - Contractual term (years) 3 Stock price $ 1.74 1.95
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Fair Value Measurements Warrant Valuation Assumptions	The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2021 and 2020: Summary of Fair Value Measurements Warrant Valuation Assumptions Year Ended December 31, 2021 2020 Risk-free interest rate 0.75% 0.18% Volatility 110.55% 116.77% Dividend yield - - Expected term (years) 2.07 3.07 Weighted-average fair value $ 1.40 $ 1.40

5. Prepaid Expenses and Other_2

5. Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are comprised of the following (in thousands): Schedule of Prepaid Expenses and Other Current Assets December 31, 2021 2020 Prepaid insurance $ 59 $ 50 Prepaid clinical costs 4,481 1,743 Other 187 39 Prepaid expenses and other current assets $ 4,727 $ 1,832

8. Accrued Expenses (Tables)

8. Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses are comprised of the following (in thousands): Schedule of Accrued Liabilities December 31, 2021 2020 Professional fees $ 181 $ 292 Personnel related 1,303 756 Outside research and development services 2,219 764 Other 25 112 Accrued expenses, net $ 3,728 $ 1,924

9. Debt (Tables)

9. Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Maturities of Long-term Debt	Scheduled maturities with respect to the 2021 Convertible Notes are as follows (in thousands): Maturities of Long-term Debt Year Ending December 31: 2022 $ 917 2023 $ 11,111 2024 $ 10,194 2025 $ - 2026 $ - Total $ 22,222

10. Stockholders' Equity (Table

10. Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary of Warrant Activity	A summary of warrant activity during the year ended December 31, 2021 is as follows (in thousands): Summary of Warrant Activity Weighted- Weighted- Average Average Remaining Exercise Contractual Life Warrants Price (in years) Outstanding as of December 31, 2019 3,584 $ 3.86 Issued 6,648 $ 0.84 Exercised (154) $ 0.30 Cancelled (12) $ 18.00 Outstanding as of December 31, 2020 10,066 $ 1.84 4.4 Issued - $ - Exercised (7,431) $ 0.98 Cancelled - $ - Outstanding as of December 31, 2021 2,635 $ 4.29 2.4 Exercisable as of December 31, 2021 2,635 $ 4.29 2.4

11. Stock-Based Compensation (T

11. Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Valuation Assumptions for Stock Options	The following assumptions were used in determining the fair value of the stock options granted during the years ended December 31, 2021 and 2020: Schedule of Valuation Assumptions for Stock Options Year Ended December 31, 2021 2020 Risk-free interest rate 0.5 1.2 0.3 1.7 Volatility 118 125 109 119 Dividend yield - - Expected term (years) 5 6 5 7 Weighted-average fair value $ 3.46 $ 0.97
Schedule of Valuation Assumptions for Stock Options	A summary of stock option activity during the year ended December 31, 2021 is as follows (in thousands, except exercise prices and years): Schedule of Valuation Assumptions for Stock Options Weighted Weighted Total Average Average Remaining Aggregate Stock Exercise Contractual Intrinsic Options Price Life (in years) Value Outstanding as of December 31, 2020 5,120 $ 1.97 Granted 2,316 3.94 Exercised (81) 1.40 Cancelled (49) 2.06 Outstanding as of December 31, 2021 7,306 $ 2.60 8.5 $ 2,180 Vested and expected to vest as of December 31, 2021 7,306 $ 2.60 8.5 $ 2,180 Exercisable as of December 31, 2021 2,245 $ 2.99 8.1 $ 856
Schedule of Stock-Based Compensation Expense	The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands): Schedule of Stock-Based Compensation Expense Year Ended December 31, 2021 2020 Research and development $ 717 $ 394 General and administrative 7,630 1,650 $ 8,347 $ 2,044

12. Income Taxes (Tables)

12. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets consist of the following (in thousands): Schedule of Deferred Tax Assets December 31, 2021 2020 Net operating tax loss carryforwards $ 30,751 $ 15,223 Accrued expenses - 66 Contingent payment obligations 407 - Stock-based compensation 3,208 521 Intangible assets 16,970 12,320 Total deferred tax asset 51,336 28,130 Less valuation allowance (51,336) (28,130) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2021 and 2020, are as follows: Schedule of Effective Income Tax Rate Reconciliation Year Ended December 31, 2021 2020 Federal statutory tax rate 21.0 % 21.0 % State and local taxes, net of federal benefit 12.9 % 11.2 % Permanent items (1.1) % (1.0) % Deferred rate changes 2.3 % 0.1 % Other 0.0 % 59.3 % Change in valuation allowance (35.1) % (90.6) % Income tax provision (benefit) - % - %

13. Commitments and Contingen_2

13. Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum operating lease payments	As of December 31, 2021, future minimum lease payments for the Company’s operating leases with a non-cancelable term of more than one year is as follows (in thousands): Schedule of future minimum operating lease payments Operating Leases Remaining Period Ended December 31, 2021 $ - Year Ended December 31, 2022 40 Total 40 Less present value discount (2) Operating lease liabilities $ 38

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded	16,045,000	23,742,000
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded	7,306,000	5,120,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded	2,400,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded	2,635,000	10,066,000
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded	3,704,000	8,556,000

2. Liquidity and Going Concern

2. Liquidity and Going Concern (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 78,734	$ 15,662
Retained Earnings (Accumulated Deficit)	$ 141,210	$ 75,162

Schedule of Fair Value Hierarch

Schedule of Fair Value Hierarchy Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 78,734	$ 15,662	$ 10,261
Liabilities [Abstract]
Derivative Liability	1,174
Fair Value, Recurring [Member]
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value	78,734	15,662
Liabilities [Abstract]
Derivative Liability	20,518
Fair Value, Recurring [Member] | Long-term Debt [Member]
Liabilities [Abstract]
Derivative Liability	18,920
Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities [Abstract]
Derivative Liability	1,174
Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Derivative Liability	424	1,062
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value	78,734	15,662
Liabilities [Abstract]
Derivative Liability	1,174
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Long-term Debt [Member]
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities [Abstract]
Derivative Liability	1,174
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Long-term Debt [Member]
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Derivative Liability
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Assets [Abstract]
Cash and Cash Equivalents, at Carrying Value
Liabilities [Abstract]
Derivative Liability	19,344
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Long-term Debt [Member]
Liabilities [Abstract]
Derivative Liability	18,920
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Derivative Liability	$ 424	$ 1,062

Summary of Fair Value Measureme

Summary of Fair Value Measurements Derivative Valuation Assumptions (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Financial Instruments, Liabilities [Member]	12 Months Ended
	Dec. 31, 2021$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	11000.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	1 month 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.88

Summary of Fair Value Measure_2

Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Long-term Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years
Long-term Debt [Member] | Minimum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.74
Long-term Debt [Member] | Maximum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.95
Share-based Payment Arrangement, Option [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years	7 years
Share-based Payment Arrangement, Option [Member] | Long-term Debt [Member] | Minimum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	90.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	1130000.00%
Share-based Payment Arrangement, Option [Member] | Long-term Debt [Member] | Maximum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	95.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	1140000.00%

Summary of Fair Value Measure_3

Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.75%	0.18%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	11055.00%	11677.00%
Dividend yield (in percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 25 days	3 years 25 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.40	$ 1.40

Schedule of Fair Value Level 3

Schedule of Fair Value Level 3 Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 424	$ 1,062	$ 963
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	(1,155)	(124)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	517	$ 223
Long-term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	18,920
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	(230)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	19,150
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	1,174
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	369
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	$ 805

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 59	$ 50
Prepaid clinical costs	4,481	1,743
Other	187	39
Prepaid expenses and other current assets	$ 4,727	$ 1,832

6. Common Stock Offerings (Deta

6. Common Stock Offerings (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

8 Months Ended

12 Months Ended

Jan. 31, 2022

Nov. 30, 2021

Dec. 31, 2020

Sep. 30, 2020

May 31, 2020

Mar. 31, 2020

Feb. 28, 2020

Jan. 31, 2020

Aug. 31, 2019

Aug. 30, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2021

Dec. 31, 2020

May 24, 2021

Jan. 28, 2021

Sep. 09, 2020

Mar. 16, 2020

Feb. 19, 2020

Feb. 13, 2020

Cash received from stock sale

$ 97,957,000

$ 8,850,000

Research and Development Expense

46,649,000

$ 10,984,000

I X License Agreement [Member]

Research and Development Expense

$ 9,000,000

[custom:NonrefundableCashPayment]

$ 1,200,000

$ 3,500,000

[custom:Issuanceofcommonstockforlicenseacquiredshares]

2,570,266

[custom:MinimumStockValueOfSharesIssued]

$ 5,500,000

[custom:InitialStockValuationShortfallFrom5.5MillionValue]

$ 800,000

November And December 2021 [Member]

Number of shares of common stock issued

540,147

Cash received from stock sale

$ 20,200,000

December 2020 [Member]

Number of shares of common stock issued

1,112,219

Cash received from stock sale

$ 10,900,000

September 42020 [Member]

Number of shares of common stock issued

8,865,000

Cash received from stock sale

$ 6,400,000

Warrant terms and provisions

The Company also issued to the investors warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the "September 2020 Warrants"). The September 2020 Warrants have an exercise price of $0.84 per share of common stock, became exercisable beginning on March 9, 2021 and will expire on March 9, 2026.

Shares Issued, Price Per Share

$ 0.79

August 2019 [Member]

Number of shares of common stock issued

4,475,000

Cash received from stock sale

$ 6,700,000

Warrant terms and provisions

The Company issued to the investors warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance. The combined purchase price for one share and one warrant to purchase half of a share of common stock in the offerings was $1.50. Roth Capital Partners, LLC (“Roth”) served as the placement agent for the issuance and sale of the shares and the warrants, and the Company paid Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company in the offerings.

May 242021 [Member]

Number of shares of common stock issued

22,258,066

Cash received from stock sale

$ 64,500,000

Shares Issued, Price Per Share

$ 3.10

Offering proceeds used to partially repay certain convertible promissory notes

$ 7,300,000

January 282021 [Member]

Number of shares of common stock issued

17,530,488

Cash received from stock sale

$ 33,500,000

Shares Issued, Price Per Share

$ 2.05

Offering proceeds used to partially repay certain convertible promissory notes

$ 3,800,000

March 162020 [Member]

Number of shares of common stock issued

7,500,000

Cash received from stock sale

$ 4,000,000

Shares Issued, Price Per Share

$ 0.60

February 132020 [Member]

Number of shares of common stock issued

6,666,667

Cash received from stock sale

$ 4,800,000

Shares Issued, Price Per Share

$ 0.75

February 192020 [Member]

Number of shares of common stock issued

999,999

Shares Issued, Price Per Share

$ 0.75

January 22020 [Member]

Number of shares of common stock issued

1,809,845

May 112020 [Member]

Number of shares of common stock issued

300,000

Other Nonrecurring Expense

$ 431,000

January 242019 [Member]

Warrant terms and provisions

Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STI’s common stock which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company’s common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein (the “Series A Warrants”), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein (the “Series B Warrants” together with the Series A Warrants, the “Investor Warrants”), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 10). The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given that the liability exceeded the proceeds received, a loss of $5.0 million was recognized.

March 72019 [Member]

Warrant terms and provisions

On March 7, 2019, the Company entered into Amendment Agreements (collectively, the “Amendment Agreements”) with each Investor amending: (i) the Purchase Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements.

Series A Warrants unexercised

300,000

300,000

7. License Agreements (Details

7. License Agreements (Details Narrative) - USD ($)	1 Months Ended																	2 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2022	Nov. 30, 2021	Sep. 30, 2021	Jan. 31, 2021	Jul. 31, 2020	Apr. 30, 2020	Feb. 29, 2020	Jan. 31, 2020	Oct. 31, 2019	Aug. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Feb. 28, 2019	Jan. 31, 2019	May 31, 2018	Mar. 31, 2018	Sep. 30, 2016	Dec. 31, 2021	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020
Business Combination, Separately Recognized Transactions [Line Items]
Research and development expense																					$ 46,649,000	$ 10,984,000
Licensefrom Ligand Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description																	On September 21, 2016, the Company entered into a License Agreement (the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.
Shares of common stock issued																				801,253
Research and development expense																				$ 2,200,000
Contingent non-refundable regulatory milestone payment upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product																		$ 750,000			750,000
Contingent non-refundable regulatory milestone payment upon FDA approval of an application for a particular Licensed Product																		3,000,000			3,000,000
Contingent non-refundable regulatory milestone payment upon regulatory approval in a Major Market for a particular Licensed Product																		1,125,000			1,125,000
Contingent non-refundable regulatory milestone payment upon regulatory approval in a second Major Market for a particular Licensed Product																		1,125,000			1,125,000
Contingent non-refundable regulatory milestone payment in connection with Aplindore upon submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product																		100,000			100,000
Contingent non-refundable regulatory milestone payment in connection with Aplindore upon FDA approval of an application for such a particular Licensed Product																		350,000			350,000
Contingent non-refundable regulatory milestone payment in connection with Aplindore upon regulatory approval in a Major Market for such a particular Licensed Product																		125,000			125,000
Contingent non-refundable regulatory milestone payment in connection with Aplindore upon regulatory approval in a second Major Market for such a particular Licensed Product																		125,000			125,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore																		10,000,000			10,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist																		10,000,000			10,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen																		10,000,000			10,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists																		10,000,000			10,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore																		20,000,000			20,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist																		20,000,000			20,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen																		20,000,000			20,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists																		20,000,000			20,000,000
Milestone payments accrued																		0			0
Assetsfrom Vyera Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description																On March 6, 2018, the Company entered into the Vyera Agreement with Vyera, pursuant to which the Company acquired the assets (the “Vyera Assets”) and liabilities (the “Vyera Assumed Liabilities”), of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002
Shares of common stock issued								1,809,845												191,529
Milestone payments accrued																		0			0
Non-refundable cash payment														$ 150,000	$ 150,000					$ 1,000,000
Cash payments agreed to in Amendment to the Asset Purchase Agreement					$ 1,000,000	$ 1,000,000		$ 750,000	$ 750,000
[custom:CashPaymentsforLowerRoyaltyPercentageonPotentialNetSalesofSLS002]			$ 3,000,000
Contingent non-refundable milestone payment upon approval by the FDA of an NDA, with respect to SLS-002																		10,000,000			10,000,000
Contingent non-refundable milestone payment upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market																		5,000,000			5,000,000
Contingent non-refundable milestone payment upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a second Major Market																		2,500,000			2,500,000
Contingent non-refundable milestone payment upon the achievement of $250.0 million in net sales of SLS-002																		5,000,000			5,000,000
Contingent non-refundable milestone payment upon the achievement of $500.0 million in net sales of SLS-002																		10,000,000			10,000,000
Contingent non-refundable milestone payment upon the achievement of $1.0 billion in net sales of SLS-002																		15,000,000			15,000,000
Contingent non-refundable milestone payment upon the achievement of $1.5 billion in net sales of SLS-002																		20,000,000			20,000,000
Contingent non-refundable milestone payment upon the achievement of $2.0 billion in net sales of SLS-002																		25,000,000			25,000,000
Weg License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description										On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020 and $0.125 million on January 2, 2021. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company’s common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the “Milestone Product”), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, and (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage
Milestone payments accrued																		0			0
Non-refundable cash payment	$ 200,000			$ 125,000				$ 100,000
Contingent non-refundable milestone payment upon the issuance of the first patent directed to an anxiety indication																		100,000			100,000
Contingent non-refundable milestone share value of common stock payment upon the issuance of the first patent directed to an anxiety indication																		150,000			150,000
Contingent non-refundable milestone payment after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission unde																		500,000			500,000
Contingent non-refundable milestone payment upon FDA approval of an NDA for the Milestone Product																		3,000,000			3,000,000
Contingent non-refundable milestone payment upon regulatory approval by the EMA for the Milestone Product																		2,000,000			2,000,000
Contingent non-refundable milestone payment upon regulatory approval in Japan for the Milestone Product																		1,500,000			1,500,000
Maximum amount to be paid under milestones																		$ 6,600,000			$ 6,600,000
Percentage of royalty payments																		2.25%			2.25%
Assetsfrom Bioblast Pharma [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description													On February 15, 2019, the Company entered into an Asset Purchase Agreement (the “Bioblast Asset Purchase Agreement”) with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the “Bioblast Asset Purchase”). The Company paid to Bioblast $1.5 million in February 2019 and an additional $2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during the three months ended March 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the completion of the Company’s first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates, the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with Team Sanfilippo Foundation (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome. TSF, upon approval by the FDA, planned to begin an open label, Phase II(b) clinical trial in up to 20 patients with Sanfilippo Syndrome, which is now known under the study name SLS-005. The Company will provide the clinical supply of Trehalose. The terms of the Bioblast Asset Purchase Agreement entitle the Company access to all clinical data from this trial. On July 15, 2019, TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million towards the funding of the trial.
Research and development expense																				3,500,000
Milestone payments accrued																		$ 0			$ 0
Non-refundable cash payment							$ 2,000,000						$ 1,500,000
Percentage of royalty payments																		1.00%			1.00%
Contingent additional milestone consideration within 15 days following the completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria																		$ 8,500,000			$ 8,500,000
Contingent additional milestone consideration within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates																		8,500,000			8,500,000
Future grant revenue contingent on Phase II (b)/III Sanfilippo clinical trial																		1,500,000			1,500,000
U C Regents License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description												On March 7, 2019, the Company entered into an exclusive license agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the three months ended March 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company’s license to a nonexclusive license.
Research and development expense																				$ 100,000
Milestone payments accrued																		0			0
Non-refundable cash payment												$ 100,000
Contingent milestone payment within 90 days following the completion of dosing of the first patient in a Phase I clinical trial																		50,000			50,000
Contingent milestone payment within 90 days following dosing of the first patient in a Phase II clinical trial																		100,000			100,000
Contingent milestone payment within 90 days following dosing of the first patient in a Phase III clinical trial																		300,000			300,000
Contingent milestone payment within 90 days following the first commercial sales in the U.S.																		1,000,000			1,000,000
Contingent milestone payment within 90 days following the first commercial sales in any European market																		1,000,000			1,000,000
Contingent milestone payment within 90 days following $250 million in cumulative worldwide net sales of a licensed product																		2,500,000			2,500,000
Duke License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description											On June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the synuclein alpha (“SNCA”) gene, which encodes alpha-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the three months ended September 30, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement.
Research and development expense																			$ 100,000
Milestone payments accrued																		0			0
Non-refundable cash payment											$ 100,000
Contingent milestone payment within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform																		100,000			100,000
Contingent milestone payment within 30 days following dosing of the first patient in a Phase I clinical trial																		200,000			200,000
Contingent milestone payment within 30 days following dosing of the first patient in a Phase II clinical trial																		500,000			500,000
Contingent milestone payment within 30 days following dosing of the first patient in a Phase III clinical trial																		1,000,000			1,000,000
Contingent milestone payment within 30 days following an NDA approval																		2,000,000			$ 2,000,000
I X License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
License agreement description		On November 24, 2021, the Company entered into an exclusive license agreement (the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of Wafermine™ and certain other existing and to be developed iXBEL wafer-based delivery technologies, in all cases for sublingual administration of ketamine. In addition, iXBEL will supply the Company with sufficient product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted iXBEL an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake limited, non-exclusive research and development activities in the territory. The Company further agreed not to undertake certain activities with respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement.
Research and development expense		$ 9,000,000
Non-refundable cash payment	$ 1,200,000	$ 3,500,000
[custom:Issuanceofcommonstockforlicenseacquiredshares]		2,570,266
Minimum stock value of shares issued		$ 5,500,000
Stock valuation shortfall from 5.5 million value																		$ 1,200,000

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Professional fees	$ 181	$ 292
Personnel related	1,303	756
Outside research and development services	2,219	764
Other	25	112
Accrued expenses, net	$ 3,728	$ 1,924

Maturities of Long-term Debt (D

Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2021USD ($)
Year Ending December 31:
2022	$ 917
2023	11,111
2024	10,194
2025
2026
Total	$ 22,222

9. Debt (Details Narrative)

9. Debt (Details Narrative) - USD ($)	1 Months Ended				12 Months Ended
	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2020	May 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 02, 2021
Short-term Debt [Line Items]
Proceeds from Convertible Debt					$ 20,203,000	$ 10,907,000
[custom:GainLossInFairValueOfConvertibleNotes]					230,000
Vovember 2021 Lind Securities Purchase Agreement [Member]
Short-term Debt [Line Items]
Long-term Debt, Description		On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock.
December 2021 S P As [Member]
Short-term Debt [Line Items]
Long-term Debt, Description	On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note.
Proceeds from Convertible Debt	$ 20,200,000
Convertible Subordinated Debt	18,900,000				$ 18,900,000		$ 19,200,000
[custom:GainLossInFairValueOfConvertibleNotes]	$ 200,000
Lind Securities Purchase Agreement [Member]
Short-term Debt [Line Items]
Long-term Debt, Description			On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of our remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.
December 17 S P As [Member]
Short-term Debt [Line Items]
Long-term Debt, Description			On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of our remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.
P P P Loan [Member]
Short-term Debt [Line Items]
Long-term Debt, Description				On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the “PPP Lender”), for an aggregate principal amount of approximately $147,000 (the “PPP Loan”). The PPP Loan bore interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, had a term of two years, and was unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program upon the Company’s request to the extent that the PPP Loan proceeds were used to pay expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company applied for and received full forgiveness of the PPP Loan with respect to these covered expenses and recorded a gain on forgiveness of debt during the year ended December 31, 2021
Debt Instrument, Face Amount				$ 147,000
Debt Instrument, Interest Rate, Stated Percentage				100.00%

Summary of Warrant Activity (De

Summary of Warrant Activity (Details) - Warrant Derivative Financial Instruments [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Offsetting Assets [Line Items]
Outstanding as of December 31, 2020	10,066,000	3,584,000
Outstanding as of December 31, weighted-average exercise price (in usd per share)	$ 1.84	$ 3.86
Warrants issued		6,648,000
Warrants issued, warrant exercise price		$ 0.84
Warrants exercised	(7,431,000)	(154,000)
Warrants exercised, exercise price of warrants	$ 98	$ 0.30
Warrants cancelled		(12,000)
Warrants cancelled, exercise price of warrants		$ 18
[custom:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife]	2 years 4 months 24 days	4 years 4 months 24 days
Outstanding as of December 31, 2021	2,635,000	10,066,000
Outstanding as of December 31, weighted-average exercise price (in usd per share)	$ 4.29	$ 1.84
Warrants exercisable as of December 31	2,635,000
Warrants exercisable, weighted-average exercise price (in usd per share)	$ 4.29
Warrants exercisable as of December 31, 2021, weighted-average remaining contractual life (in years)	2 years 4 months 24 days

10. Stockholders' Equity (Detai

10. Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2019	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Preferred Stock, Shares Authorized		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding		0	0
Common stock, authorized (in shares)		240,000,000	120,000,000
Common stock voting right		Each share of common stock is entitled to one voting right
Proceeds from Warrant Exercises		$ 7,252,000	$ 45,000
September 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares of common stock issued	6,648,750
[custom:WarrantsExercisable-0]		1,000,000
August 232019 [Member]
Class of Warrant or Right [Line Items]
Number of shares of common stock issued	4,475,000
August 2019 Warrants [Member]
Class of Warrant or Right [Line Items]
[custom:WarrantsExercisable-0]		900,000
September 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant description		The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026.
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.84
Date on which warrants became exercisable		Mar. 9, 2021
[custom:NumberofWarrantsExercisedDuringPeriod]		5,600,000
Proceeds from Warrant Exercises		$ 4,700,000
August 2019 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant description		On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.78
Date on which warrants became exercisable		Feb. 27, 2020
[custom:NumberofWarrantsExercisedDuringPeriod]		1,300,000
Proceeds from Warrant Exercises		$ 2,400,000
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant description		The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.2957
[custom:NumberofWarrantsExercisedDuringPeriod]		500,000	200,000
Proceeds from Warrant Exercises		$ 100,000	$ 45,000
[custom:WarrantsExercisable-0]		300,000

Schedule of Valuation Assumptio

Schedule of Valuation Assumptions for Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	50.00%	30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	120.00%	170.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.46	$ 0.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,210,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 300,000	$ 0
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	118.00%	109.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	125.00%	119.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years	7 years
Stock Optionsand Director Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	5,120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 1.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,316,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 3.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(81,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 1.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(49,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 2.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	7,306,000	5,120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 2.60	$ 1.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 2,180,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	7,306,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 2.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	8 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 2,180,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,245,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 2.99
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 856,000

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 8,347	$ 2,044
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	717	394
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 7,630	$ 1,650

11. Stock-Based Compensation (D

11. Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,400,000
Share-based Payment Arrangement, Noncash Expense	$ 8,347,000	$ 2,044,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description	The Company has the Amended and Restated Apricus 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. As of December 31, 2021, an aggregate of 11,110,431 shares of common stock were authorized under the Apricus 2012 Plan, of which 1.4 million shares of common stock were available for future grants. Upon completion of the Merger, the Company assumed the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (the “2016 Plan”) and awards outstanding under the 2016 Plan became awards for common stock. Effective as of the Merger, no further awards may be issued under the 2016 Plan.
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	11,110,431
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	During the year ended December 31, 2021, the Company granted 2,210,000 stock options to employees with a weighted average exercise price per share of $4.04 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,210,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 300,000	$ 0
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 7,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 1 month 6 days
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description	On May 15, 2020, the Company’s stockholders approved the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”), whereby qualified employees are allowed to purchase limited amounts of the Company’s common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company’s common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company’s Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company on or prior to each such January 1. On January 1, 2021, the Company added 545,358 shares for purchase by employees under the ESPP. During the year ended December 31, 2021, the Company sold 80,009 shares under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $72,000 for the year ended December 31, 2021.
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	0.85%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms	On January 1, 2021, the Company added 545,358 shares for purchase by employees under the ESPP.
Stock Issued During Period, Shares, Employee Stock Purchase Plans	80,009
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 72,000
Inducement Planof 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description	On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan is substantially similar to the 2016 Plan. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	During the year ended December 31, 2021, the Company also granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	106,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.67
Performance Shares [Member] | P S Uto Executives [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award is subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards are unvested and three of the five performance conditions have been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. The Company does not believe that the achievement of the remaining two performance criteria is probable at this time. Unrecognized compensation expense will be recognized only once the performance condition is probable of being achieved and only for the cumulative amount related to the service condition that has been fulfilled. As of December 31, 2021, the Company had $1.3 million of unrecognized compensation expense related to performance conditions considered probable which will be recognized over 0.2 years. As of December 31, 2021, the Company had unrecognized compensation expense of $4.1 million for performance conditions that were considered not probable of achievement.
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 4.31
Share-based Payment Arrangement, Noncash Expense			$ 4,900,000
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 1,300,000
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized for Performance Not Probable, Amount	$ 4,100,000

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating tax loss carryforwards	$ 30,751	$ 15,223
Accrued expenses		66
Contingent payment obligations	407
Stock-based compensation	3,208	521
Intangible assets	16,970	12,320
Total deferred tax asset	51,336	28,130
Less valuation allowance	(51,336)	(28,130)
Net deferred tax asset

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory tax rate	2100.00%	2100.00%
State and local taxes, net of federal benefit	1290.00%	1120.00%
Permanent items	(110.00%)	(100.00%)
Deferred rate changes	230.00%	10.00%
Other	0.00%	5930.00%
Change in valuation allowance	(3510.00%)	(9060.00%)
Income tax provision (benefit)

12. Income Taxes (Details Narra

12. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Noncurrent deferred tax asset, gross	$ 30,800,000	$ 15,200,000
Open Tax Year	2018
Tax examination penalties and interest expense	$ 0	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward	89,400,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$ 400,000
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 89,000,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward	$ 175,500,000
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036

Schedule of future minimum oper

Schedule of future minimum operating lease payments (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remaining Period Ended December 31, 2021
Year Ended December 31, 2022	40
Total	40
Less present value discount	(2)
Operating lease liabilities	$ 38

13. Commitments and Contingen_3

13. Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset	$ 39,000		$ 74,000
Operating Lease, Liability	$ 38,000
Operating Lease, Weighted Average Remaining Lease Term	292 days
Operating Lease, Weighted Average Discount Rate, Percent	800.00%
Operating Lease, Expense	$ 100,000	$ 100,000
March 2019 Lease [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Description	In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019 the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.
March 2021 Lease [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Description	In March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month.
Lessee, Operating Lease, Option to Extend	This agreement includes one or more renewal options.
Operating Lease, Right-of-Use Asset	$ 39,000
Operating Lease, Liability	$ 38,000

14. Subsequent Events (Details

14. Subsequent Events (Details Narrative) - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2022	Nov. 30, 2021
I X License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
[custom:NonrefundableCashPayment]	$ 1.2	$ 3.5